THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced that it will hold a conference call on Wednesday, May 28, 2008, beginning at 8 a.m. Eastern Time to discuss the results of the denosumab Phase 3 head-to-head study versus alendronate (the “141” study) at the upcoming European Symposium on Calcified Tissues (ECTS) Conference in Barcelona, Spain. Speakers will include the principal study investigator, Jacques P. Brown, M.D., Head, Division of Rheumatology, Le Centre hospitalier universitaire de Québec, and Catherine Stehman-Breen, M.D., Amgen’s vice president, Global Development – Bone Therapeutic Area.
